Zilbrysq now approved in Canada to treat adults with generalized MG
UCB’s injection therapy Zilbrysq (zilucoplan) has gained approval in Canada for treating adults with generalized myasthenia gravis (gMG)…
Articles by Andrea Lobo
New Phase 3 trial data support efficacy of nipocalimab in gMG
Treatment with nipocalimab led to significant reductions in disease severity among people with generalized myasthenia gravis (gMG), as…
Cancer therapy Keytruda triggers MG in elderly man: Case report
Treatment with Keytruda (pembrolizumab), an immune checkpoint inhibitor (ICI) used to treat cancer, may trigger myasthenia gravis (MG), according…
1st patient dosed in NMD670 trial for generalized myasthenia gravis
NMD Pharma announced the dosing of the first patient in a Phase 2b clinical trial of NMD670, its investigational…
Post-thymectomy myasthenia gravis disease severity, relapse rate linked
A greater reduction in disease severity a month after surgery to remove the thymus gland in myasthenia gravis (MG)…
IL-41 may be potential biomarker as levels correlate with MG severity
Blood levels of interleukin-41 (IL-41) — a signaling molecule involved in immune responses — are found to be significantly elevated…
‘Hot Line,’ other patient initiatives mark MGFA annual conference
The 2024 National Patient Conference by the Myasthenia Gravis Foundation of America (MGFA) brought together more than 400 members…
Having MG significantly hinders patients’ ability to work, study finds
People with myasthenia gravis (MG) — particularly those with more severe symptoms — are significantly hindered both in their…
Unusual symptoms of ocular MG in young girl ease after treatment
A young girl who showed unusual symptoms of ocular myasthenia gravis — persistent upper eyelid droopiness and outward deviation…
Rescue therapy use can reduce myasthenic crisis deaths: Scientists
Timely rescue therapy use during a myasthenic crisis — a life-threatening complication of myasthenia gravis (MG) marked by…